Short-term Safety of Covaxin, Sinopharm, Sputnik V, and AstraZeneca COVID-19 Vaccines Among Iranian Healthcare Workers: A Cross-Sectional Study
Authors:
- Reza SinaeiRSReza Sinaei
- Mohammad Javad NajafzadehMNMohammad Javad Najafzadeh
- Somayeh GhafariSGSomayeh Ghafari
- Ali HosseininasabAHAli Hosseininasab
- Abbas PardakhtyAPAbbas Pardakhty
- Behnam DalfardiBDBehnam Dalfardi
- Maysam YousefiMYMaysam Yousefi
- Ali SinaeiASAli Sinaei
- Sara PezeshkiSPSara Pezeshki
- Roya SinaeiRSRoya Sinaei
- Azam DehghaniADAzam Dehghani
- Fatemeh Karami RobatiFRFatemeh Karami Robati
Open Access
- 9 January 2024
- journal article
- research article
- Published by Brieflands in Archives of Clinical Infectious Diseases
- Vol. 19 (1)
Abstract
Background: Several coronavirus disease 2019 (COVID-19) vaccines, utilizing different platforms, have successfully obtained emergency clinical use authorization to prevent severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infections. Most published data from COVID-19 vaccine trials have frequently observed mild-to-moderate side effects, with varying severity depending on various vaccine types. Objectives: This study aimed to estimate the prevalence of side effects associated with four types of COVID-19 vaccines among vaccinated healthcare workers following the first and second vaccine doses and to identify possible risk factors for COVID-19 vaccine side effects. Methods: This cross-sectional study was conducted from April 2021 to March 2022 by administering a questionnaire and conducting direct interviews with healthcare workers in Kerman, southeastern Iran, who had received 2 or more doses of COVID-19 vaccines. Results: Out of 861 individuals enrolled in the study, 38.7% received Sputnik, 32.4% AstraZeneca, 19.6% Covaxin, and 9.3% Sinopharm vaccines. Overall, the most common side effects after the first and second doses included general symptoms, fever and chills, injection site reactions, neurological symptoms, and gastrointestinal symptoms. Furthermore, the frequency of symptoms significantly reduced after the second dose. Conclusions: General symptoms and injection site reactions were significantly more common after receiving the first dose of vaccines compared to the second dose. No severe vaccine side effects were observed in this study. However, further research is required to evaluate the long-term symptoms and safety profiles of COVID-19 vaccines.Keywords
This publication has 28 references indexed in Scilit:
- Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trialThe Lancet Infectious Diseases, 2021
- The Inclusive Review on SARS-CoV-2 Biology, Epidemiology, Diagnosis, and Potential Management OptionsCurrent Microbiology, 2021
- Efficacy and Safety of the mRNA-1273 SARS-CoV-2 VaccineNew England Journal of Medicine, 2021
- Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in RussiaThe Lancet, 2021
- Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UKThe Lancet, 2021
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 VaccineNew England Journal of Medicine, 2020
- Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity OutcomesJAMA, 2020
- Herd Immunity: Understanding COVID-19Immunity, 2020
- Novel coronavirus 2019-nCoV: prevalence, biological and clinical characteristics comparison with SARS-CoV and MERS-CoV2020
- Building Confidence in Vaccines2012